Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31616445 | 1.00 | TSHR (0.39) | TSHRGSTP1 | |
| SCHEMBL24894194 | 1.00 | TSHR (0.39) | TSHRGSTP1 | |
| SCHEMBL17793345 | 1.00 | TSHR (0.39) | TSHRGSTP1 | |
| SCHEMBL12092218 | 1.00 | TSHR (0.39) | TSHRGSTP1 | |
| SCHEMBL17776277 | 1.00 | TSHR (0.39) | TSHRGSTP1 | |
| SCHEMBL3489296 | 0.97 | TSHR (0.41) | TSHRGSTP1 | |
| SCHEMBL12092217 | 0.88 | PSMB8 (0.30) | — | |
| SCHEMBL27252354 | 0.88 | TSHR (0.36) | TSHR | |
| SCHEMBL31656393 | 0.88 | TSHR (0.36) | TSHR | |
| SCHEMBL18751700 | 0.87 | PSMB8 (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114272389-B | Eribulin-based antibody-drug conjugates and methods of use | 卫材研究发展管理有限公司 | 2023-04-18 | — | — | CN | disclosed |
| CN-114272389-A | Eribulin-based antibody-drug conjugates and methods of use | 卫材研究发展管理有限公司 | 2022-04-05 | — | — | CN | disclosed |
| CN-114191563-A | Eribulin-based antibody-drug conjugates and methods of use | 卫材研究发展管理有限公司 | 2022-03-18 | — | — | CN | disclosed |
| CN-114191428-A | Eribulin-based antibody-drug conjugates and methods of use | 卫材研究发展管理有限公司 | 2022-03-18 | — | — | CN | disclosed |
| US-20210094975-A1 | RAPAMYCIN ANALOGS AS MTOR INHIBITORS | Revolution Medicines, Inc. | 2021-04-01 | — | — | US | disclosed |
| US-8952147-B2 | Conjugates, preparation thereof, and therapeutic use thereof | SANOFI (FR) | 2015-02-10 | — | — | US | disclosed |
| US-8952147-B2 | Conjugates, preparation thereof, and therapeutic use thereof | SANOFI (FR) | 2015-02-10 | — | — | US | disclosed |
| US-20120225089-A1 | NOVEL CONJUGATES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2012-09-06 | — | — | US | disclosed |
| US-20120225089-A1 | NOVEL CONJUGATES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2012-09-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120225089-A1 | NOVEL CONJUGATES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF | ERG28, CARS1, FOLH1 | TSHR 4077/4885GSTP1 186/4885 |
| US-20210094975-A1 | RAPAMYCIN ANALOGS AS MTOR INHIBITORS | MTOR, RICTOR, RPTOR | TSHR 3837/4885GSTP1 3745/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.